Skip to main content

Search Videos and More

Showing 37 - 48 of 50 results

Previous| 1... 3 | 4 | 5 |Next

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

Professor Bhatt, you presented the pharmacoeconomic “in trial” analysis for alirocumab based on the ODYSSEY Outcomes Trial. Can you discuss the clinical implications of your analysis, and how reduced costs for alirocumab will affect IC practice?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

From an interventional cardiology perspective, what did ODYSSEY Outcomes teach us about the large subgroup of diabetic patients who had ACS plus stent insertions?

A confluence of events has reshaped the accessibility, evidence basis, and actionability profile for PCSK9 inhibitors. As an atherosclerosis specialist, how have these developments changed the equation and shaped your approach to CV risk reduction?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

How do you approach the diabetic patient who also has a constellation of multiple high-risk features, above and beyond the underlay of diabetes? What is the relative and absolute benefit of employing PCSK9 inhibitors in this patient population?

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process?

In the interventional cardiology setting, what percentage of your patients do not achieve the ESC Lipid Guideline goal of 70 mg/dL and, therefore, are suitable candidates for PCSK9 inhibition? Can you discuss your patient selection process?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

What have we learned from the ODYSSEY Outcomes pharmacoeconomic analysis that you and Professor Deepak Bhatt reported at the AHA 2018 Meeting? And what are the implications for the clinician-cardiologist who is making the case to payors?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What should the approach be in patients who have had a coronary event with an LDL-C level of 70 mg/dL? Do the outcome studies with PCSK9 inhibitors provide an evidentiary roadmap for this common situation?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

What LDL-C target goals should a consulting or treating medical cardiologist recommend for patients with Type 2 diabetes—with a known ACS event vs. diabetes alone as a risk factor?

Showing 37 - 48 of 50 results

Previous| 1... 3 | 4 | 5 |Next